Thu, Sep 18, 2014, 5:11 AM EDT - U.S. Markets open in 4 hrs 19 mins


% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

hnllvs 6 posts  |  Last Activity: Sep 12, 2014 7:52 AM Member since: Jun 20, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hnllvs by hnllvs Sep 12, 2014 7:52 AM Flag

    Form 8-K for ONCOTHYREON INC.


    Other Events

    Item 8.01 Other Events.
    Merck KGaA, Darmstadt, Germany, today announced that its biopharmaceutical division Merck Serono will discontinue the clinical development program of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). The decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients.

    Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies.

    Merck KGaA has world-wide rights for the development and commercialization of tecemotide under a license agreement with Oncothyreon.

  • Reply to

    No Doubling to Happen

    by emptor_of_ooze Sep 5, 2014 12:51 PM
    hnllvs hnllvs Sep 8, 2014 10:20 AM Flag

    Every single time kirkman opens his mouth ONTY goes down. Slam dunk.

  • I wonder if some traders believed for a short time that Roche was going to buy PACB a couple weeks ago when
    PACB jumped up dramatically and quickly . When word 'leaked' it was not PACB that was to be the next roche target the stock dripped back down. Just a theory.

  • A million shares in less then 90 minutes. Down 70+ cents. Will definately take many moons to snap back from this hammering.

  • Reply to

    Looks like we...

    by hnllvs Jul 25, 2014 9:43 AM
    hnllvs hnllvs Jul 25, 2014 9:44 AM Flag

    correction....SUB 5.

  • are headed back to sub 4. Obvious the street was not impressed by this report.

22.94+0.64(+2.87%)Sep 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.